Low Dose IL-2 Therapy in Sjögren’s

Save

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Tyk2 Inhibition Effective in SLE

Save

Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.

How Underweight Women Can Reduce Hip Fracture Risk

Save

How women can reduce the risk of hip fracture?  

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Save

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 

I loved the city, but not the convention center (not easy to navigate). 

ACR Best Abstracts - Day 3

Save

The last day was jammed with important reports and research including the late breaking abstracts. 

ACR Best Abstracts - Day 2

Save

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:

Are MDA criteria created equal in PsA?

Save

Minimal Disease Activity criteria are used to evaluate PsA disease activity and response to treatment. Given that a patient only has to meet 5 of the 7 criteria, should the individual components be weighted equally? 

Are we really treating Psoriatic disease if we only address active disease domains and T2T?

Save

It’s widely accepted that Psoriatic disease has multi-system, multi-domain potential that can lead to life altering complications if left untreated or undertreated. Rheumatologists have shifted the way we discuss treatment options and disease state expectations with patients. Two #ACR22 abstracts stood out to me regarding the Psoriatic disease patient experience and will, ultimately, add to what I do in clinic. 

Proposed Cancer Screening for Inflammatory Myositis Patients

Save

Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.  Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this thorny practice issue. 

Anifrolumab shows long-term promise in patients with lupus

Save

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.

Creaky Joints Presentations at ACR Convergence 2022

Save

The patient advocacy organization CreakyJoints will present 13 scientific posters at this year's ACR Convergence 2022 and 8 posters as part of the patient perspectives track. Below is a sampling of these scientific posters. 

New 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis

Save

The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.

ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs

Save

New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other consensus treatment plans by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).

ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment

Save

On Sunday Nov. 13, 2022, at ACR Convergence 2022 meeting, the ACR will present a new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis.

Video Telehealth Willingness Increased During Pandemic

Save

Americans’ willingness to use video telehealth has increased since the beginning of the COVID-19 pandemic, rising most sharply among Black Americans and people with less education, according to a new RAND Corporation study.

Opportunistic Infections with JAK inhibitors in RA

Save

Winthrop and colleagues have reviewd the occurrence of opportunistic infections (OIs) associated with the use of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), showing that Herpez zoster (HZ) was the most common OI reported with JAK inhibitors in clinical trials, althou

2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections

Save

A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).

Women with Rheumatic Disease (11.4.2022)

Save

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

Undiagnosed RA During the Pandemic

Save

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.